Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Antimicrobial Activity of α-Peptide/β-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant Pseudomonas aeruginosa Isolated From Cystic Fibrosis Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Staphylococcus saprophyticus From Clinical and Environmental Origins Have Distinct Biofilm Composition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Rapid Open-Source SNP-Based Clustering Offers an Alternative to Core Genome MLST for Outbreak Tracing in a Hospital Setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Azole-Resistant Aspergillus fumigatus Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Involvement of NLRP3 and NLRC4 Inflammasome in Uropathogenic E. coli Mediated Urinary Tract Infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pandemics: past, present, future: That is like choosing between cholera and plague

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in Pseudomonas aeruginosa in a Murine Biofilm Wound Model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Pseudomonas aeruginosa infection is a predominant cause of morbidity and mortality in patients with cystic fibrosis infection and with a compromised immune system. Emergence of bacterial resistance renders existing antibiotics inefficient, and therefore discovery of new antimicrobial agents is highly warranted. In recent years, numerous studies have demonstrated that antimicrobial peptides (AMPs) constitute potent agents against a range of pathogenic bacteria. However, AMPs possess a number of drawbacks such as susceptibility to proteolytic degradation with ensuing low bioavailability. To circumvent these undesired properties of AMPs unnatural amino acids or altered backbones have been incorporated to provide stable peptidomimetics with retained antibacterial activity. Here, we report on antimicrobial α-peptide/β-peptoid lysine-based peptidomimetics that exhibit high potency against clinical drug-resistant P. aeruginosa strains obtained from cystic fibrosis patients. These clinical strains possess phoQ and/or pmrB mutations that confer high resistance to colistin, the last-resort antibiotic for treatment of infections caused by P. aeruginosa. The lead peptidomimetic LBP-2 demonstrated a 12-fold improved anti-pseudomonal activity as compared to colistin sulfate as well as favorable killing kinetics, similar antibiofilm activity, and moderate cytotoxicity.

OriginalsprogEngelsk
TidsskriftFrontiers in Microbiology
Vol/bind10
Sider (fra-til)275
ISSN1664-302X
DOI
StatusUdgivet - 2019

ID: 59045832